ImmunoGen ( IMGN -4% ) appoints Sandra E. Poole as SVP, Technical Operations reporting to CEO Daniel Junius. She joins the firm from Genzyme where she was SVP of biologics manufacturing. Post your comment!
Genzyme (NYSE: SNY ) (NASDAQ: GCVRZ ) presents interim results from an extension study of Lemtrada ( alemtuzumab ) today at the European
In an interview with Reuters , Genzyme 's (NYSE: SNY ) (NASDAQ: GCVRZ ) chief of its multiple sclerosis franchise Bill Sibold says his firm intends to be a leader
PARIS, Sept 11 (Reuters) - Sanofi rare disease unit Genzyme said its Lemtrada multiple sclerosis (MS) drug showed continued efficacy for four years in more than two thirds of patients and that no new safety risks had been identified in its latest studies.
PARIS, Sept 11 (Reuters) - Sanofi rare disease unit Genzyme hopes to become a leader in the multiple sclerosis (MS) field with the help of new products developed in-house but also through...
the Medley, Chattem, Merial, and Genzyme acquisitions all have generated returns ..... than four years. Additionally, the Genzyme acquisition shows how Sanofi avoided ..... value rights, or CVR, to appease Genzyme . Further, Viehbacher's decision
The FDA clears Genzyme 's ( SNY -0.3% ) Cerdelga (eliglustat) an oral therapy for the ..... fatty materials by inhibiting the metabolic process that forms them. Genzyme 's first drug for Type 1 Gaucher disease was Ceredase ( alglucerase
recently acquired Cell Therapy and Regenerative Medicine (CTRM) business from Sanofi (NYSE: SNY ), previously known as Genzyme Biosurgery Aps. Total revenues for the quarter were approximately $4.4 million, and were comprised of approximately
approximately one in a million people in the U.S., according to scientific studies, which made Juxtapid an orphan drug . Genzyme 's Kynamro, which has also been developed to treat HoFH, has also been granted an orphan drug status. Interestingly
and substantially increased its presence in the lucrative biotechnology arena earlier this decade with the addition of Genzyme , is a diversified powerhouse, with a product portfolio that includes seven blockbusters and dozens of medicines/vaccines